Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia 4Melanoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Gliosarcoma 2Glioblastoma 2Congenital Abnormalities 2Central Nervous System Neoplasms 2Brain Neoplasms 2Astrocytoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Metastatic Solid Tumors 1Meningioma 1Medulloblastoma 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Glioma, Subependymal 1Glioma 1Familial ependymoma 1Fallopian Tube Neoplasms 1Ependymoma 1

Interventions

Cyclophosphamide 220Rituximab 189fludarabine phosphate 169fludarabine 102Peripheral Blood Stem Cell Transplantation 100Mycophenolic Acid 94Whole-Body Irradiation 81Tacrolimus 72Filgrastim 69Cyclosporine 67Lenalidomide 66ibrutinib 63Busulfan 61Melphalan 58Antilymphocyte Serum 57Radiotherapy 52venetoclax 48Etoposide 47obinutuzumab 42Bendamustine Hydrochloride 42Alemtuzumab 41Methotrexate 39ofatumumab 28sargramostim 27Granulocyte Colony-Stimulating Factor 26Cytarabine 26Cord Blood Stem Cell Transplantation 26acalabrutinib 25Stem Cell Transplantation 24Specimen Handling 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Lymphocytic, Chronic, B-Cell × FANG vaccine × Clear all
NCT00343447 2012-05-03

Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡